1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea is a **synthetic organic compound**, also known as **DMPNU**. It is **not a naturally occurring molecule** and was likely created in a laboratory setting.
**It is important for research because:**
* **Potential biological activity:** DMPNU likely exhibits some sort of biological activity, making it a potential candidate for pharmacological research.
* **Structural analysis:** DMPNU has a complex molecular structure containing several functional groups (methoxy, nitro, and urea). Studying its structure and properties can help researchers understand how such molecules interact with biological systems.
* **Synthesis and methodology:** The synthesis of DMPNU itself can be a topic of research. Researchers may be interested in developing new and efficient methods for synthesizing this compound or its derivatives.
**However, without additional context, it's impossible to pinpoint the specific research area where DMPNU is crucial.**
**To determine its exact importance, you'd need more information about:**
* **The research field:** Is it related to drug discovery, materials science, organic synthesis, or something else?
* **The specific research question:** What problem is being addressed by studying DMPNU?
* **The properties of DMPNU:** What specific biological or chemical properties make it interesting to researchers?
With more information, we can better understand the role of 1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea in research.
ID Source | ID |
---|---|
PubMed CID | 970899 |
CHEMBL ID | 1313140 |
CHEBI ID | 112373 |
Synonym |
---|
n-(3,4-dimethoxyphenyl)-n'-(2-methoxy-5-nitrophenyl)urea |
MLS000621272 |
smr000294290 |
1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea |
STK460563 |
CHEBI:112373 |
AKOS003341024 |
HMS2678P12 |
CHEMBL1313140 |
Q27192477 |
sr-01000277541 |
SR-01000277541-1 |
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
WRN | Homo sapiens (human) | Potency | 79.4328 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 14.5750 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 24.5192 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 1.9953 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
67.9K protein | Vaccinia virus | Potency | 19.0919 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 79.4328 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
DNA polymerase beta | Homo sapiens (human) | Potency | 19.9526 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 25.6651 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |